Roger Adsett

“I'm delighted to provide some detail on BRINSUPRI's performance. In its first partial quarter of launch, BRINSUPRI achieved $28 million in net sales. We are very pleased by the strength of the BRINSUPRI launch in these early days and the reception it has received from the treating and patient communities.”

“It's a pleasure to be with you this morning. As I reflect on the resources invested in the preparation for brensocatib's U.S. launch, it's apparent to me that the team is well positioned to execute on this opportunity.”

“From an operational perspective, I want to focus on two key areas today. First, I'll discuss the commercial operations related to ARIKAYCE, and then I'll cover the growth of our second pillar, brensocatib, along with the new clinical indications we plan to pursue.”

“From an operational perspective, Insmed made important progress during the third quarter. ARIKAYCE now has a commercial presence in three major territories: the U.S., Europe, and Japan.”

“From an operational perspective, Insmed continued to make important advancements during the second quarter. Our global commercial footprint expanded during the quarter, and ARIKAYCE has now launched in the U.S., Europe, and Japan.”